Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction RegimenRobert M. Rifkin, Stephen J. Noga, Saad Z. Usmani et al.|Blood|2017Cited by 5
PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)Robert M. Rifkin, Ralph V. Boccia, Habte Yimer et al.|HemaSphere|2019Cited by 1